Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Jun;17(6):732-6.
doi: 10.1007/s11695-007-9135-x.

Intragastric injection of botulinum toxin A for the treatment of obesity

Reinhard Mittermair  1 , Christian Keller, John Geibel
Affiliations
Randomized Controlled Trial

Intragastric injection of botulinum toxin A for the treatment of obesity

Reinhard Mittermair et al. Obes Surg. 2007 Jun.

Erratum in

  • Obes Surg. 2007 Jul;17(7):996

Abstract

Background: Botulinum toxin A (BTX-A) is a powerful and long-acting inhibitor of muscular contractions in both striated and smooth muscles. Hypothetically, BTX-A should inhibit the acetylcholine-mediated peristalsis, which is mainly responsible for gastric motility, and thereby induce slowed gastric emptying, earlier satiety and weight loss. The aim of this study was to observe the effects of endoscopic intragastric injections of BTX-A in obese patients.

Methods: After approval by the University Ethics Committee, 10 female patients with class I obesity (body mass index 30-35) were double-blind randomized into 2 groups (BTX-A and 0.9% Saline). In Group 1, 200 U BTX-A were injected endoscopically into the antrum and the distal gastric body. In Group 2, 0.9% saline was injected endoscopically into the antrum and the distal gastric body. Body weight and feeling of satiety were recorded monthly over a period of 6 months.

Results: Both groups (BTX-A and 0.9% Saline) showed no significant weight reduction (P>0.05). One patient in Group 1 and two patients in Group 2 reported a feeling of early satiety. No adverse effects related to BTX-A or complications resulting from the endoscopic procedure were observed.

Conclusion: Intragastric injection of BTX-A for the treatment of obesity does not seem to reduce body weight.

PubMed Disclaimer

References

    1. Dermatol Surg. 1996 Jan;22(1):39-43 - PubMed
    1. Aliment Pharmacol Ther. 2000 Jun;14(6):829-34 - PubMed
    1. Gastroenterol Clin Biol. 2005 Aug-Sep;29(8-9):789-91 - PubMed
    1. Aliment Pharmacol Ther. 2003 Jul 1;18(1):1-16 - PubMed
    1. Ann Intern Med. 1994 Oct 15;121(8):590-1 - PubMed

Publication types

Substances

LinkOut - more resources